Orchestra BioMed Holdings, Inc.OBIOEarnings & Financial Report
Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.
OBIO Q4 FY2025 Key Financial Metrics
Revenue
$30.9M
Gross Profit
$30.9M
Operating Profit
$6.8M
Net Profit
$6.2M
Gross Margin
99.8%
Operating Margin
21.8%
Net Margin
20.2%
YoY Growth
12120.2%
EPS
$0.28
Orchestra BioMed Holdings, Inc. Q4 FY2025 Financial Summary
Orchestra BioMed Holdings, Inc. reported revenue of $30.9M (up 12120.2% YoY) for Q4 FY2025, with a net profit of $6.2M (up 138.7% YoY) (20.2% margin). Cost of goods sold was $51.0K, operating expenses totaled $24.1M.
Key Financial Metrics
| Total Revenue | $30.9M |
|---|---|
| Net Profit | $6.2M |
| Gross Margin | 99.8% |
| Operating Margin | 21.8% |
| Report Period | Q4 FY2025 |
Income Statement
| Q4 2025 | |
|---|---|
| Revenue | $30.9M |
| YoY Growth | 12120.2% |
Balance Sheet
| Q4 2025 | |
|---|---|
| Assets | $114.9M |
| Liabilities | $51.5M |
| Equity | $53.6M |
Cash Flow
| Q4 2025 | |
|---|---|
| Operating CF | $-2.3M |